Tumor Biology

, Volume 37, Issue 2, pp 1863–1869 | Cite as

Caveolin-1 overexpression in benign and malignant salivary gland tumors

  • Zohreh Jaafari-Ashkavandi
  • Mohammad Javad Ashraf
  • Ali Dehghani Nazhvani
  • Zahra Azizi
Original Article


Caveolin-1, a tyrosine-phosphorylated protein, is supposed to have different regulatory roles as promoter or suppressor in many human cancers. However, no published study concerned its expression in benign and malignant salivary gland tumors. The aim of this study was to evaluate and compare the expression of Cav-1 in the most common benign and malignant salivary gland tumors and evaluate its correlation with proliferation activity. In this cross-sectional retrospective study, immunohistochemical expression of caveolin-1 and Ki67 were evaluated in 49 samples, including 11 normal salivary glands, 15 cases of pleomorphic adenoma (PA), 13 adenoid cystic carcinomas (AdCC), and 10 mucoepidermoid carcinomas (MEC). The expression of Cav-1 was seen in 18 % of normal salivary glands and 85 % of tumors. The immunoreaction in the tumors was significantly higher than normal tissues (P = 0.001), but the difference between benign and malignant tumors was not significant (P = 0.07). Expression of Cav-1 was correlated with Ki67 labeling index in PAs, but not in malignant tumors. Cav-1 expression was not in association with tumor size and stage. Overexpression of Cav-1 was found in salivary gland tumors in comparison with normal tissues, but no significant difference was observed between benign and malignant tumors. Cav-1 was inversely correlated with proliferation in PA. Therefore, this marker may participate in tumorigenesis of salivary gland tumors and may be a potential biomarker for cancer treatments.


Salivary gland tumor Caveolin-1 Ki67 Pleomorphic adenoma Adenoid cystic carcinoma Mucoepidermoid carcinoma 



The authors thank the Vice-Chancellery of Shiraz University of Medical Science for supporting this research (Grant No. 92-01-03-6272). The authors would like to thank Dr. Sh. Hamedani (DDS, MSc) for helping with the English and editorial assistance in the manuscript and Dr. M. Vossoughi from the Dental Research Development Centre for the statistical analysis. This manuscript is related to the undergraduate thesis of Z. Azizi (Shiraz University of Medical Science, Shiraz, Iran).


  1. 1.
    Jaafari-Ashkavandi Z, Ashraf MJ, Moshaverinia M. Salivary gland tumors: a clinicopathologic study of 366 cases in southern Iran. Asian Pac J Cancer Prev. 2013;14(1):27–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Stenman G, Persson F, Andersson MK. Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol. 2014;50(8):683–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Nagao T, Sato E, Inoue R, Oshiro HH, Takahashi R, Nagai T, et al. Immunohistochemical analysis of salivary gland tumors: application for surgical pathology practice. Acta Histochem Cytochem. 2012;45(5):269–82.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Jaafari- Ashkavandi Z, Najvani AD, Tadbir AA, Pardis S, Ranjbar MA, Ashraf MJ. MCM3 as a novel diagnostic marker in benign and malignant salivary gland tumors. Asian Pac J Cancer Prev. 2013;14(6):3479–82.CrossRefGoogle Scholar
  5. 5.
    Hehlgans S, Cordes N. Caveolin-1: an essential modulator of cancer cell radio- and chemoresistance. Am J Cancer Res. 2011;1(4):521–30.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Hung KF, Lin SC, Liu CJ, Chang CS, Chang KW, Kao SY. The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. J Oral Pathol Med. 2003;32(8):461–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Lajoie P, Nabi RI. Lipid rafts, caveolae, and their endocytosis. Int Rev Cell Mol Biol. 2010;282:135–63.CrossRefPubMedGoogle Scholar
  8. 8.
    Yang G, Timme TL, Naruishi K, Fujita T, el Fattah MA, Cao G, et al. Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol. 2008;84(2):131–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Du C, Chen L, Zhang H, Wang Z, Liu W, Xie X, et al. Caveolin-1 limits the contribution of BKCa channel to MCF-7 breast cancer cell proliferation and invasion. Int J Mol Sci. 2014;15(11):20706–22.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yang G, Addai J, Wheeler TM, Frolov A, Miles BJ, Kadmon D, et al. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007;38(11):1688–95.CrossRefPubMedGoogle Scholar
  11. 11.
    Park JH, Ryu JM, Han HJ. Involvement of caveolin-1 in fibronectin-induced mouse embryonic stem cell proliferation: role of FAK, RhoA, PI3K/Akt, and ERK 1/2 pathways. J Cell Physiol. 2011;226(1):267–75.CrossRefPubMedGoogle Scholar
  12. 12.
    Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008;27(4):715–35.CrossRefPubMedGoogle Scholar
  13. 13.
    Tanase CP, Dima S, Mihai M, Raducan E, Nicolescu MI, Albulescu L, et al. Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. J Mol Histol. 2009;40(1):23–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Belanger MM, Roussel E, Couet J. Caveolin-1 is down-regulated in human lung carcinoma and acts as a candidate tumor suppressor gene. Chest. 2004;125(5 Suppl):106s.CrossRefPubMedGoogle Scholar
  15. 15.
    Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001;159(5):1635–43.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Shi L, Chen XM, Wang L, Zhang L, Chen Z. Expression of caveolin-1 in mucoepidermoid carcinoma of the salivary glands: correlation with vascular endothelial growth factor, microvessel density, and clinical outcome. Cancer. 2007;109(8):1523–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009;174(6):2023–34.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007;67(6):614–22.CrossRefPubMedGoogle Scholar
  19. 19.
    Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007;13(1):90–101.CrossRefPubMedGoogle Scholar
  20. 20.
    Cokakli M, Erdal E, Nart D, Yilmaz F, Sagol O, Kilic M, et al. Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer. 2009;9:65.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol. 2009;174(6):2035–43.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001;1(1):46–54.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tajika Y, Matsuzaki T, Suzuki T, Aoki T, Hagiwara H, Tanaka S, et al. Immunohistochemical characterization of the intracellular pool of water channel aquaporin-2 in the rat kidney. Anat Sci Int. 2002;77(3):189–95.CrossRefPubMedGoogle Scholar
  24. 24.
    Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, et al. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol. 2003;162(4):1241–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Liu X, Wang W, Singh BB, Lockwich T, Jadlowiec J, O’Connell B, et al. Trp1, a candidate protein for the store-operated Ca(2+) influx mechanism in salivary gland cells. J Biol Chem. 2000;275(5):3403–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Rathor N, Chung HK, Wang SR, Wang JY, Turner DJ, Rao JN. Caveolin-1 enhances rapid mucosal restitution by activating TRPC1-mediated Ca2+ signaling. Physiol Rep. 2014;3:2(11).Google Scholar
  27. 27.
    Zhang ZB, Cai L, Zheng SG, Xiong Y, Dong JH. Overexpression of caveolin-1 in hepatocellular carcinoma with metastasis and worse prognosis: correlation with vascular endothelial growth factor, microvessel density and unpaired artery. Pathol Oncol Res. 2009;15(3):495–502.CrossRefPubMedGoogle Scholar
  28. 28.
    Yerian LM, Anders RA, Tretiakova M, Hart J. Caveolin and thrombospondin expression during hepatocellular carcinogenesis. Am J Surg Pathol. 2004;28(3):357–64.CrossRefPubMedGoogle Scholar
  29. 29.
    Kim HA, Kim KH, Lee RA. Expression of caveolin-1 is correlated with Akt-1 in colorectal cancer tissues. Exp Mol Pathol. 2006;80(2):165–70.CrossRefPubMedGoogle Scholar
  30. 30.
    Ma WY, Zhuang L, Cai DX, Zhong H, Zhao C, Sun Q. Inverse correlation between caveolin-1 expression and clinical severity in psoriasis vulgaris. J Int Med Res. 2012;40(5):1745–51.CrossRefPubMedGoogle Scholar
  31. 31.
    Faggi F, Chiarelli N, Colombi M, Mitola S, Ronca R, Madaro L, et al. Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma. Lab Invest. 2015;95(6):585–602.CrossRefPubMedGoogle Scholar
  32. 32.
    Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC, Clarke R. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J Biol Chem. 2007;282(8):5934–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Zou H, Volonte D, Galbiati F. Interaction of Caveolin-1 with Ku70 inhibits Bax-mediated apoptosis. PLoS One. 2012;7(6), e39379.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Schwab W, Harada H, Goetz W, Nowicki M, Witt M, Kasper M, et al. Immunocytochemical and biochemical detection of EMMPRIN in the rat tooth germ: differentiation-dependent co-expression with MMPs and co-localization with caveolin-1 in membrane rafts of dental epithelial cells. Histochem Cell Biol. 2007;128(3):195–203.CrossRefPubMedGoogle Scholar
  35. 35.
    Jaafari- Ashkavandi Z, Pardis S, Asadzadeh M, Andisheh-Tadbir A, Dehghani-Nazhvani A. Caveolin-1 expression in odontogenic cysts and ameloblastomas. Turk Patoloji Derg. 2014;30(2):94–9.PubMedGoogle Scholar
  36. 36.
    Ando T, Ishiguro H, Kimura M, Mitsui A, Mori Y, Sugito N, et al. The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol Rep. 2007;18(3):601–9.PubMedGoogle Scholar
  37. 37.
    Moon KC, Lee GK, Yoo SH, Jeon YK, Chung JH, Han J, et al. Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Res. 2005;25(6c):4631–7.PubMedGoogle Scholar
  38. 38.
    Liedtke C, Kersting C, Burger H, Kiesel L, Wulfing P. Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol. 2007;5:110.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Zohreh Jaafari-Ashkavandi
    • 1
  • Mohammad Javad Ashraf
    • 2
  • Ali Dehghani Nazhvani
    • 1
  • Zahra Azizi
    • 3
  1. 1.Department of Oral and Maxillofacial Pathology, School of DentistryShiraz University of Medical SciencesShirazIran
  2. 2.Department of Pathology, School of MedicineShiraz University of Medical SciencesShirazIran
  3. 3.Shiraz University of Medical SciencesShirazIran

Personalised recommendations